Actively Recruiting
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
Led by Zhujiang Hospital · Updated on 2025-09-25
20
Participants Needed
1
Research Sites
308 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical research study is to learn if azacitidine combined with Chidamide will help to control the disease in patients with high-risk AML after an allogeneic stem cell transplant. The safety of this combination will also be studied.
CONDITIONS
Official Title
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 60 years old, both male and female
- Able to understand and sign informed consent
- Diagnosed with AML not M3 according to the 2016 WHO AML Classification
- Have AML with poor genetic abnormalities, primary refractory AML, relapsed AML, or secondary AML
- ECOG performance status of 0, 1, 2, or 3
- Expected survival time of 3 months or longer
- Non-hematological toxicity related to transplantation does not exceed Grade 2
- Laboratory requirements before treatment start:
- Bilirubin, ALT, and AST less than 3 times the upper limit of normal
- Neutrophil count greater than 1.5 x 10^9/L without G-CSF treatment, measured twice at least 2 days apart within 7 days before treatment
- Platelet count greater than 80 x 10^9/L without platelet transfusion, measured twice at least 2 days apart within 7 days before treatment
- Serum creatinine clearance rate greater than 30 ml/min
You will not qualify if you...
- Uncontrollable active infection
- Active hepatitis B, hepatitis C, or HIV infection before enrollment
- Grade III-IV graft-versus-host disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nanfang Hospital of Southern Medical University
Guanzhou, Guandong, China, 510250
Actively Recruiting
Research Team
R
Rui Huang, Doctor
CONTACT
Y
Yunqing Wang, Bachelor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here